Today, Dec. 22, the U.S. Food and Drug Administration has issued an emergency use authorization for Pfizer’s Paxlovid for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients, 12 and older.
Data from Pfizer’s clinical trial shows the oral pill is 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness.
From the FDA:
‘Today’s authorization introduces the first treatment for COVID-19 that is in the form of a pill that is taken orally — a major step forward in the fight against this global pandemic,’ said Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research. ‘This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19.’
U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus. https://t.co/lhgeVE79uR
— CBS 13 News (@WGME) December 22, 2021